Gunda Pristauz1, Jochen B Geigl, Edgar Petru. 1. Klinische Abteilung für Gynäkologie, Universitätsklinik für Frauenheilkunde und Geburtshilfe, Medizinische Universität Graz, Graz, Osterreich. gunda.pristauz@klinikum-graz.at
Abstract
BACKGROUND: In total, 5-10% of all breast cancer cases are related to gen mutations. In most cases a mutation in the BRCA1-gen and BRCA2-gen is responsible for insufficient repair of DNA damages that cause breast and ovarian cancer. CLINICAL MANAGEMENT: In patients carrying BRCA1-mutation the risk for developing breast and ovarian cancer is 87% and 40% as well as 47% and 20% for those carrying a BRCA2-mutation. Women at hereditary risk should be informed about existing recommendations for surveillance. Primary prevention of breast and ovarian cancer including prophylactic surgery (bilateral salpingoophorectomy and bilateral mastectomy) should be explained to mutation carriers. The issue of oral antihormonal therapy for prevention of breast cancer should be addressed. Psycho-social support should be offered to mutation carriers. CONCLUSIONS: The clinical management of BRCA1 and BRCA2-mutation carriers is very challenging and should be done in centres specialized in this issue.
BACKGROUND: In total, 5-10% of all breast cancer cases are related to gen mutations. In most cases a mutation in the BRCA1-gen and BRCA2-gen is responsible for insufficient repair of DNA damages that cause breast and ovarian cancer. CLINICAL MANAGEMENT: In patients carrying BRCA1-mutation the risk for developing breast and ovarian cancer is 87% and 40% as well as 47% and 20% for those carrying a BRCA2-mutation. Women at hereditary risk should be informed about existing recommendations for surveillance. Primary prevention of breast and ovarian cancer including prophylactic surgery (bilateral salpingoophorectomy and bilateral mastectomy) should be explained to mutation carriers. The issue of oral antihormonal therapy for prevention of breast cancer should be addressed. Psycho-social support should be offered to mutation carriers. CONCLUSIONS: The clinical management of BRCA1 and BRCA2-mutation carriers is very challenging and should be done in centres specialized in this issue.
Authors: L S Friedman; S A Gayther; T Kurosaki; D Gordon; B Noble; G Casey; B A Ponder; H Anton-Culver Journal: Am J Hum Genet Date: 1997-02 Impact factor: 11.025
Authors: M C King; S Wieand; K Hale; M Lee; T Walsh; K Owens; J Tait; L Ford; B K Dunn; J Costantino; L Wickerham; N Wolmark; B Fisher Journal: JAMA Date: 2001-11-14 Impact factor: 56.272
Authors: Roger L Milne; Julia A Knight; Esther M John; Gillian S Dite; Ronald Balbuena; Argyrios Ziogas; Irene L Andrulis; Dee W West; Frederick P Li; Melissa C Southey; Graham G Giles; Margaret R E McCredie; John L Hopper; Alice S Whittemore Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-02 Impact factor: 4.254
Authors: Andrea Eisen; Jan Lubinski; Jan Klijn; Pal Moller; Henry T Lynch; Kenneth Offit; Barbara Weber; Tim Rebbeck; Susan L Neuhausen; Parviz Ghadirian; William D Foulkes; Ruth Gershoni-Baruch; Eitan Friedman; Gadi Rennert; Teresa Wagner; Claudine Isaacs; Charmaine Kim-Sing; Peter Ainsworth; Ping Sun; Steven A Narod Journal: J Clin Oncol Date: 2005-10-20 Impact factor: 44.544
Authors: Tomas Kirchhoff; Noah D Kauff; Nandita Mitra; Kedoudja Nafa; Helen Huang; Crystal Palmer; Tony Gulati; Eve Wadsworth; Sheri Donat; Mark E Robson; Nathan A Ellis; Kenneth Offit Journal: Clin Cancer Res Date: 2004-05-01 Impact factor: 12.531
Authors: Timothy R Rebbeck; Tara Friebel; Henry T Lynch; Susan L Neuhausen; Laura van 't Veer; Judy E Garber; Gareth R Evans; Steven A Narod; Claudine Isaacs; Ellen Matloff; Mary B Daly; Olufunmilayo I Olopade; Barbara L Weber Journal: J Clin Oncol Date: 2004-02-23 Impact factor: 44.544